Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients.
Piazza
R G
RG
Magistroni
V
V
Andreoni
F
F
Franceschino
A
A
Tornaghi
L
L
Varella-Garcia
M
M
Bungaro
S
S
Colnaghi
F
F
Corneo
G
G
Pogliani
E M
EM
Gambacorti-Passerini
C
C
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D001549:Benzamides; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D010879:Piperazines / Q000008:administration & dosage*; D011743:Pyrimidines / Q000008:administration & dosage*; D016896:Treatment Outcome
D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate